Showing 2901-2910 of 3039 results for "".
- Allergan Agrees to Split CEO, Chairman Roles at Next Leadership Transitionhttps://modernod.com/news/allergan-agrees-to-split-ceo-chairman-roles-at-next-leadership-transition/2476413/Allergan disclosed in a US Securities and Exchange Commission filing on Friday that it has agreed to split its chairman and chief executive roles, both currently held by CEO Brent Saunders, at the next leadership transition. The company said that splitting the roles now, as hedge fund Appaloosa h
- SynergEyes Launches Tangible Hydra-PEG Coating on SynergEyes VS Scleral Lenshttps://modernod.com/news/synergeyes-launches-tangible-hydra-peg-coating-on-synergeyes-vs-scleral-lens/2476394/SynergEyes announced that the SynergEyes VS scleral lens is now available with Tangible Hydra-PEG on Contamac material. The Tangible Hydra-PEG coating is designed to solve the problem of contact lens discomfort and dry eyes by minimizing deposits and lens fogging, increasing lens surface water re
- Nicox Initiates Phase 2 Trial of NCX 4251 in Blepharitishttps://modernod.com/news/nicox-initiates-phase-2-trial-of-ncx-4251-in-blepharitis/2476393/Nicox SA announced the initiation of a phase 2 clinical trial evaluating NCX 4251, its novel patented ophthalmic suspension of fluticasone propionate nanocrystals, being developed as the first targeted topical treatm
- GenSight Biologics to Present 72-Week Data From the REVERSE Phase 3 Trial of GS010https://modernod.com/news/gensight-biologics-to-present-72-week-data-from-the-reverse-phase-3-trial-of-gs010/2476389/GenSight Biologics announced that the 72-week results from the REVERSE Phase 3 clinical trial of GS010 will be presented at the 45th Annual Meeting of the North American Neuro-Ophthalmology Society (NANOS), which will be held in Las Vegas from March 16 to 21, 2019. The results will be presented b
- Aerpio Pharmaceuticals Does Not Meet Primary Endpoint in Phase 2b Study for Diabetic Retinopathyhttps://modernod.com/news/aerpio-pharmaceuticals-does-not-meet-primary-endpoint-in-phase-2b-study-for-diabetic-retinopathy/2476386/Aerpio Pharmaceuticals announced topline results from the company’s TIME-2b study, a phase 2b clinical trial designed to assess the efficacy and safety of Aerpio’s lead candidate, AKB-9778, for patients with moderate to severe non-proliferative diabetic retinopathy (NPDR). Administration o
- New Study Shows an Eye Scan Can Detect Signs of Alzheimer’s Diseasehttps://modernod.com/news/new-study-shows-an-eye-scan-can-detect-signs-of-alzheimers-disease/2476384/Researchers from the Duke Eye Center have shown that a new, noninvasive imaging device can see signs of Alzheimer’s disease in a matter of seconds. The researchers found that the small blood vessels in the retina at the back of the eye are altered in patients with Alzheimer’s, and showed that the
- Coburn Technologies Introduces New Spin Coater with Dual-Coating Technology, Velocity 2Dhttps://modernod.com/news/coburn-technologies-introduces-new-spin-coater-with-dual-coating-technology-velocity-2d/2476376/Coburn Technologies has introcued the Velocity 2D, the next generation of the Velocity Automated Spin Coater, now designed with dual-coating technology. Derived from the existing platform of the ground-breaking Velocity automated lens coater, the Velocity 2D now offers labs the ability to
- Dompé Receives Industry Innovation Award for Oxervate Eye Drops for Neurotrophic Keratitishttps://modernod.com/news/dompe-receives-industry-innovation-award-for-oxervate-eye-drops-for-neurotrophic-keratitis/2476372/Dompé Farmaceutici S.p.A and Dompé US Inc. announced that the National Organization for Rare Disorders (NORD) has awarded them the 2019 Industry Innovation Award for Oxervate. The Rare Impact Awards celebrate people, organizations, and innovators making exceptional contributions benefiting rare d
- ProQR Reports First Patient Dosing in Phase 1/2 STELLAR Trial of QR-421a for Usher Syndrome Type 2https://modernod.com/news/proqr-reports-first-patient-dosing-in-phase-1-2-stellar-trial-of-qr-421a-for-usher-syndrome-type-2/2476365/ProQR Therapeutics announced the first patient dosed in the phase 1/2 STELLAR clinical trial for QR-421a in patients with Usher syndrome type 2 or non-syndromic retinitis pigmentosa (RP). Interim data from the study are expected to be announced mid-2019. “There are no effective treat
- Staar Surgical Announces Strategic Cooperation Agreement with Vista Oftalmólogoshttps://modernod.com/news/staar-surgical-announces-strategic-cooperation-agreement-with-vista-oftalmologos/2479594/Staar Surgical Company announced a strategic cooperation agreement with Vista Oftalmólogos, a 49-clinic ophthalmology group spanning Spain, France, Portugal, and Morocco with more than 200 eye doctors and 1,000 employees. The agreement positions the EVO Visian ICL family of lenses as a premium an